NEW YORK, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)CANCER RESEARCH INSTITUTE INC, founded in 1953, is a mid-sized nonprofit in the Medical Research sector that reported $24.0M in total revenue in fiscal year 2023. Revenue fell 26% from the prior year — a significant decline worth monitoring. Expenses of $32.8M exceeded revenue, resulting in a 37% operating deficit.
THE CANCER RESEARCH INSTITUTE'S MISSION IS TO SAVE MORE LIVES BY FUELING THE DISCOVERY AND DEVELOPMENT OF POWERFUL IMMUNOTHERAPIES FOR ALL TYPES OF CANCER. TO ACCOMPLISH THIS, CRI FUNDS LABORATORY, TRANSLATIONAL, AND CLINICAL RESEARCH. EFFORTS AIMED AT LEARNING HOW TO HARNESS THE POWER OF THE IMMUNE SYSTEM TO DIAGNOSE, TREAT, AND CURE CANCER. CRI ALSO COORDINATES SCIENTIFIC, MEDICAL, AND PATIENT EDUCATION CONFERENCES ON THE SUBJECTS OF IMMUNOLOGY AND IMMUNOTHERAPY, AND DISSEMINATES INFORMATION IN ENGLISH AND SPANISH ABOUT ADVANCES IN TUMOR IMMUNOLOGY TO THE MEDIA, PUBLIC, AND MEDICAL AND SCIENTIFIC COMMUNITIES.
STAR PROGRAM - SEE SCHEDULE OTHE LLOYD J. OLD STAR PROGRAM PROVIDES GRANTS OF $1.25 MILLION OVER 5 YEARS TO MID-CAREER SCIENTISTS. THIS LONG-TERM FUNDING IS NOT TIED TO A SPECIFIC RESEARCH PROJECT...
STAR PROGRAM - SEE SCHEDULE OTHE LLOYD J. OLD STAR PROGRAM PROVIDES GRANTS OF $1.25 MILLION OVER 5 YEARS TO MID-CAREER SCIENTISTS. THIS LONG-TERM FUNDING IS NOT TIED TO A SPECIFIC RESEARCH PROJECT, BUT RATHER AIMS TO PROVIDE A DEGREE OF FLEXIBILITY AND FREEDOM FOR INVESTIGATORS TO EXPLORE OUTSIDE-THE-BOX AND DISRUPTIVE AVENUES OF RESEARCH. CANDIDATES SELECTED FOR THIS AWARD ARE EXPECTED TO BE FUTURE "STARS" IN THE FIELD OF CANCER IMMUNOLOGY: SCIENTISTS TAKING RISKS.
FELLOWSHIP PROGRAM - SEE SCHEDULE OTHE CRI POSTDOCTORAL FELLOWSHIP PROGRAM INCLUDES THREE TRACKS OF FELLOWSHIPS PROVIDING CAREER DEVELOPMENT, TRAINING, AND DIVERSITY BUILDING IN IMMUNOLOGY AND...
FELLOWSHIP PROGRAM - SEE SCHEDULE OTHE CRI POSTDOCTORAL FELLOWSHIP PROGRAM INCLUDES THREE TRACKS OF FELLOWSHIPS PROVIDING CAREER DEVELOPMENT, TRAINING, AND DIVERSITY BUILDING IN IMMUNOLOGY AND IMMUNO-INFOMATICS. THE CRI IRVINGTON POSTDOCTORAL FELLOWSHIP, CRI IRVINGTON POSTDOCTORAL FELLOWSHIP TO PROMOTE RACIAL DIVERSITY, AND THE CRI IMMUNO-INFORMATICS FELLOWSHIP EACH SUPPORT YOUNG IMMUNOLOGISTS AND CANCER IMMUNOLOGISTS AT TOP UNIVERSITIES AND RESEARCH CENTERS AROUND THE WORLD. FELLOWS RECEIVE UP TO $243,000 OVER THREE YEARS TO COVER THE COST OF STIPEND, INCLUDING AN INSTITUTIONAL ALLOWANCE TO HELP PAY FOR THE FELLOW'S RESEARCH SUPPLIES, TRAVEL TO SCIENTIFIC MEETINGS, HEALTH INSURANCE, AND/OR CHILDCARE. OF THE MORE THAN 1,620 CRI POSTDOCTORAL FELLOWS FUNDED TO DATE, MANY HAVE SINCE BECOME HEADS OF MAJOR MEDICAL RESEARCH INSTITUTES, ACADEMIC LEADERS IN PRESTIGIOUS UNIVERSITIES, AND ADMIRED MENTORS TO THE NEXT GENERATION OF IMMUNOLOGISTS AND TUMOR IMMUNOLOGISTS.
CRI CLINICAL INNOVATOR - SEE SCHEDULE OTHE CRI CLINICAL INNOVATOR SUPPORTS NOVEL CLINICAL STUDIES THAT ADDRESS AREAS OF HIGH UNMET NEED IN CANCER AND SEEKS MECHANISTIC INSIGHTS INTO CLINICAL RESPONSE...
CRI CLINICAL INNOVATOR - SEE SCHEDULE OTHE CRI CLINICAL INNOVATOR SUPPORTS NOVEL CLINICAL STUDIES THAT ADDRESS AREAS OF HIGH UNMET NEED IN CANCER AND SEEKS MECHANISTIC INSIGHTS INTO CLINICAL RESPONSE WITH A GOAL OF PREDICTIVE BIOMARKER DISCOVERY. TO MAXIMIZE THE IMPACT OF EACH CLINICAL TRIAL, CRI WILL ADVISE ON SELECTED STUDIES IN A COORDINATED EFFORT TO OPTIMIZE CLINICAL TRIAL DESIGN AND TRANSLATIONAL STUDIES. FUNDING OF UP TO $1M PER CLINICAL TRIAL IS AWARDED.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $23,964,638 | $32,295,259 | -0.3% |
| Expenses | $32,820,896 | $38,552,663 | -0.1% |
| Net Income | $-8,856,258 | $-6,257,404 | +0.4% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| PAUL C SHIVERICK | CHAIRMEN | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| ANDREW K TSAI | CHAIRMEN | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| DONALD J GOGEL | VICE CHAIRMEN | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| EDGAR R BERNER | VICE CHAIRMEN | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| GEOFFREY O COLEY | TREASURER | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| THOMAS G MENDELL | SECRETARY | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| TONY ALVAREZ II | TRUSTEE | 0.50 |
Director
|
$0 | $0 | $0 |
| YACOV ARNOPOLIN | TRUSTEE | 4.00 |
Director
|
$0 | $0 | $0 |
| PETER L BLOOM | TRUSTEE | 4.00 |
Director
|
$0 | $0 | $0 |
| BRIAN J BRILLE | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL R CRAWFORD | TRUSTEE (THRU 4/2024) | 1.00 |
Director
|
$0 | $0 | $0 |
| W ROBERT DAHL | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| MAXWELL DAVID | TRUSTEE | 0.25 |
Director
|
$0 | $0 | $0 |
| GLENN J DESIMONE | TRUSTEE (THRU 7/2023) | 1.00 |
Director
|
$0 | $0 | $0 |
| SEAN P FAHEY | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| WILLIAM S GOLDBERG | TRUSTEE | 0.25 |
Director
|
$0 | $0 | $0 |
| OLIVER R GRACE JR | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| SANDRA COUDERT GRAHAM | TRUSTEE | 0.50 |
Director
|
$0 | $0 | $0 |
| MICHAEL M KELLEN | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| SARAH KIM | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| FERN LAZAR | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| ALEXANDER P LYNCH | TRUSTEE (THRU 7/2023) | 1.00 |
Director
|
$0 | $0 | $0 |
| SANDRA OZOLA | TRUSTEE | 0.25 |
Director
|
$0 | $0 | $0 |
| MICHAEL J PETRICK | TRUSTEE | 0.50 |
Director
|
$0 | $0 | $0 |
| LIEF D ROSENBLATT | TRUSTEE | 0.25 |
Director
|
$0 | $0 | $0 |
| ANAND SHAH MD | TRUSTEE | 0.25 |
Director
|
$0 | $0 | $0 |
| ADAM SHAPIRO | TRUSTEE | 0.25 |
Director
|
$0 | $0 | $0 |
| FRANK V SICA | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| JAMES A STERN | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| ROBERT S STOLAR | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL B TARGOFF | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| DIANE TUFT | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| LAUREN S VERONIS | TRUSTEE | 3.00 |
Director
|
$0 | $0 | $0 |
| RONALD G WEINER | TRUSTEE | 1.00 |
Director
|
$0 | $0 | $0 |
| JIM WEISS | TRUSTEE | 4.00 |
Director
|
$0 | $0 | $0 |
| PETER ZHOU | TRUSTEE | 5.00 |
Director
|
$0 | $0 | $0 |
| ALFRED R MASSIDAS TO 22025 | CFO & DIRECTOR OF HUMAN RESOURCES | 40.00 |
Officer
|
$347,437 | $90,161 | $437,598 |
| JILL O'DONNELL TORMEY TO 824 | CEO & DIRECTOR OF SCIENTIFIC AFFAIRS | 40.00 |
Officer
|
$539,137 | $72,884 | $612,021 |
| ALICIA ZHOU PHD START 92024 | CEO | 40.00 |
Officer
|
$0 | $0 | $0 |
| KATHRYN BEELEY START 22025 | CFO | 40.00 |
Officer
|
$0 | $0 | $0 |
| DEANNE T MARBACH | DIRECTOR OF MAJOR GIFTS | 40.00 |
Key Emp
|
$155,690 | $54,575 | $210,265 |
| JAY R CAMPBELL | MANAGING DIR OF CRI CLINICAL ACCELERATOR | 40.00 |
Key Emp
|
$284,937 | $83,161 | $368,098 |
| LYNNE A RAPINO | CHIEF PROGRAM OFFICER | 40.00 |
Key Emp
|
$287,287 | $84,627 | $371,914 |
| RUPINDER KAUR | CHIEF INFORMATION OFFICER | 40.00 |
Key Emp
|
$247,910 | $64,351 | $312,261 |
| SHARON S SLADE | CHIEF MARKETING OFFICER | 40.00 |
Key Emp
|
$273,403 | $47,760 | $321,163 |
| BRIAN M BREWER | CHIEF COMMUNICATIONS OFFICER | 40.00 |
Highest
|
$148,135 | $0 | $148,135 |
| MARLA S LAWSON | ASSOC DIR OF CORPORATE RELATIONS | 40.00 |
Highest
|
$136,015 | $52,016 | $188,031 |
| QING HUA ZHANG | CONTROLLER | 40.00 |
Highest
|
$147,203 | $53,996 | $201,199 |
| SAMIK K UPADHAYA | ASST DIRECTOR, SCIENTIFIC AFFAIRS | 40.00 |
Highest
|
$145,770 | $54,210 | $199,980 |
| SHASELL NEGRON | ASSOC DIR, COMMUNITY FUNDRAISING | 40.00 |
Highest
|
$126,437 | $32,999 | $159,436 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | No data | No data | No data | No data |
| 2024 | $23,964,638 | $32,820,896 | $133,734,670 | $-8,856,258 |
| 2023 | $32,295,259 | $38,552,663 | $138,008,864 | $-6,257,404 |
| 2022 | $33,675,150 | $31,314,716 | $130,438,312 | $2,360,434 |
| 2021 | $35,987,695 | $37,138,977 | $146,547,886 | $-1,151,282 |
| 2020 | $37,223,458 | $38,496,564 | $126,564,196 | $-1,273,106 |
| 2019 | $41,995,692 | $34,748,390 | $127,608,094 | $7,247,302 |
Compare CANCER RESEARCH INSTITUTE INC with other nonprofits in New York and across the country.